Clinical trials
Phase 2 Polyradiculoneuropathy, Chronic Inflammatory Demyelinating trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
16 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2015 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 8 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Recruiting | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Immunovant Sciences GmbH | 3 |
| argenx | 2 |
| Biogen | 1 |
| Bioverativ, a Sanofi company | 1 |
| Fred Hutchinson Cancer Center | 1 |
| Mamatha Pasnoor, MD | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| Northwestern University | 1 |
| Nuvig Therapeutics, Inc. | 1 |
| Oregon Health and Science University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 16 |
| Autoimmune Diseases | 3 |
| Autoimmune Diseases of the Nervous System | 1 |
| Demyelinating Diseases | 1 |
| Lambert-Eaton Myasthenic Syndrome | 1 |
| Myasthenia Gravis | 1 |
| Neuromyelitis Optica | 1 |
| Opsoclonus-Myoclonus Syndrome | 1 |
| Paraproteinemias | 1 |
| Stiff-Person Syndrome | 1 |
Trials
Showing 1 to 16 of 16. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.